Joined January 2010
- Tweets 97
- Following 107
- Followers 91
- Likes 405
6 Photos and videos
Pinned Tweet
1 Oct 2021
It has been a fantastic last three years of my research career @CentenaryInst. I am really grateful to my mentors @Peter @JessTiffen, labmates and all other colleagues.
I am really excited and looking forward to the next phase of my research career @FisherLabMGH @harvardmed
2
1
13
16 May 2024
Delighted to share our latest work which I co-lead with @JessTiffen. Epigenetic inhibitor against BET proteins and antiCTLA-4 synergistically reduce tumor growth which are resistance to anti-PD1. Hope it can make a meaningful impact in clinical settings. @DrHYTseng @JessTiffen.
11 May 2024
More great work from my team on epigenetic BET inhibitors.
Here we show they combine well with antiCTLA-4 immune checkpoint inhibition (ICI) to combat melanoma with innate resistance to antiPD-1/L1 (frontline) ICI in a mouse model.
@DrHYTseng @emran_geb
onlinelibrary.wiley.com/doi/…
6
157
16 Aug 2023
Great piece of work from my PhD Lab .
Yet another strong evidence of epigenetic reprogramming in adaptive resistance of multiple solid tumor models. Congrats to everyone involved in this fascinating project. Happy to be a part of it. @HelmutSchaider@DinoopMenon @Heinz @HaassLab
12 Aug 2023
Hot off the press:
Drug Resist Updat, accepted 4th August 2023;
doi: doi.org/10.1016/j.drup.2023.…
Congrats to Helmut and his team and collaborators - fantastic work!
#FrazerInstUQ, @UQDRC, @UQMedicine, @TRI_info, @CUDenver, @UCSF, @otago, @JOAN_RESEARCH, @TheWistar,
2
94
29 Apr 2022
Couldn't agree more! A must-read thread..
27 Apr 2022
The Best Scientists 🧵
I have heard a lot about the Best Scientists 🧑🔬
Maybe the best scientists...
make impactful discoveries,
publish in gilded journals,
garner millions in funding,
with lots of indirects.
And prizes, all the prizes🏆
And everybody respects them.
OR…
3
16 Feb 2022
That's hilarious but harsh truth! Why can't we have both prestige and money??
2
6
9 Feb 2022
Happy to share our latest commentary article on
"Dual Targeting with EZH2 Inhibitor and STING Agonist to Treat Melanoma" based on a recent seminal work and our previous works. First from @FisherLabMGH
#Epigenetics #Melanoma
jidonline.org/article/S0022-…
1
1
10
Abdullah Al Emran retweeted
14 Dec 2021
Prof Peter Hersey is generally recognised as a pioneer of the #melanoma treatment – #immunotherapy – in Australia. Having first started treating melanoma patients in 1980, he has seen great advances in field but he is not going to stop there.
More 👉 ow.ly/PtHe50GSVvV
2
4
7 Dec 2021
29 Nov 2021
"MFN2 Stabilization: A Bridge for Endoplasmic Reticulum Stress Sensitivity in Melanoma," a commentary by Charles Adelmann, Inbal Rachmin, & David Fisher
bit.ly/3xLq5Zn #JIDJournal #dermscience
3
15 Nov 2021
Congratulations Australia for winning the maiden T20 World cup title. What a team! What a match! Super proud of you guys...
Love and respect for New Zealand. Well played. In the end, cricket wins.
#T20WorldCupFinal
espncricinfo.com/series/icc-…
8 Nov 2021
When you change a lab and start everything from the scratch...
#AcademicChatter #ResearchLife
4
4 Nov 2021
Couldn't agree more! 😁👏
1
28 Oct 2021
Many thanks for promoting our work @CentenaryInst
27 Oct 2021
LATEST NEWS: Researchers from the Centenary Institute have developed a new approach to fighting #melanomas that fail to respond – or are resistant – to standard treatments. More: centenary.org.au/cen_news/ne…
5
25 Oct 2021
Delighted to share our latest findings- "Repurposing melanoma chemotherapy to activate inflammasomes in treatment of BRAF/MAPK inhibitor resistant melanoma"
Excellent work from @Farzana& @DrHYTseng.
My #2 as a co-senior author.
@CentenaryInst @Jess @Peter
jidonline.org/article/S0022-…
8
12 Sep 2021
Couldn't agree more! Additionally, It should also be adjusted according to the living cost of some expensive states/cities. It's not a big ask and could be encouraging for the young scientist who wants to pursue their career in academia.
3
4 Sep 2021
Brilliant piece of work. A must-read for melanoma researchers.
3 Sep 2021
Why do mutations only sometimes cause cancer? In our new @ScienceMagazine paper, we describe a mechanism for this called "oncogenic competence": science.org/doi/10.1126/scie…
27 Aug 2021
Our new findings @biorxivpreprint
Happy to share our latest findings on repurposing the existing chemotherapy to induce innate inflammasomes for a potential therapeutic option of BRAF/MAPKi resistant melanoma. @Farzana @DrHYTseng @JessTiffen #PeterHersey @CentenaryInst
24 Aug 2021
Repurposing melanoma chemotherapy to activate inflammasomes in treatment of BRAF/MAPK inhibitor-resistant melanoma biorxiv.org/cgi/content/shor… #bioRxiv
1
8
29 Jun 2021
The age of epigenetic inhibitors is now and ahead for improving therapeutic efficacy in cancers. A comprehensive review on the role of histone demethylases(erasers) in melanoma other cancers from our lab. Nice work @Gaya19628293 @JessTiffen
24 Jun 2021
Lysine Demethylases: Promising Drug Targets in Melanoma and Other Cancers frontiersin.org/article/10.3… everything you need to know about lysine demethylases in cancer but didn’t know you needed to know. An excellent review from my PhD student @Gaya19628293 and @emran_geb
1
5
27 May 2021
Our paper is out now in print @JIDJournals. Thanks again to all my colleagues and collaborator. Special thanks to my mentors @JessTiffen, Stuart and Peter. Such a lovely team to work with 🙏
sciencedirect.com/science/ar…
2
1
11
27 May 2021
Another evidence from our group suggests that epigenetic inhibitors can potentially be an alternative therapeutic option for deadly melanoma.
1
25 May 2021
A fantastic achievement and thoroughly deserved. Many congrats @JessTiffen. Wishing you more success ahead. We are proud of you.
25 May 2021
LATEST NEWS: The Centenary Institute's @JessTiffen has been awarded a grant from Cancer Council NSW to investigate a new approach to reverse treatment resistance in #melanoma. centenary.org.au/cen_news/bo… @CCNSWResearch
9